Noradrenaline use for neonatal circulatory support

Area of Science:

• Neonatal Intensive Care
• Pediatric Cardiology
• Pharmacology

Background:

• Noradrenaline (NA) is used for circulatory support in neonates with sepsis and pulmonary hypertension.
• Current NA treatment protocols for neonates vary significantly across institutions.
• Understanding NA's indications, effects, and outcomes in neonates is crucial.

Purpose of the Study:

• To determine the indications, usage patterns, and effects of Noradrenaline (NA) in preterm and term infants requiring circulatory support.
• To compare outcomes between neonates who survived and those who died following NA treatment.
• To analyze NA's impact on blood pressure, perfusion, and hemodynamics.

Main Methods:

• Retrospective data analysis of 37 neonates treated with NA between January 2016 and May 2021.
• Inclusion of preterm and term infants from a single neonatal intensive care unit.
• Assessment of indications for NA use, hemodynamic parameters, and adverse events.

Main Results:

• Sepsis (30%), pulmonary hypertension (51%), and hypotension (19%) were primary indications for NA.
• Neonates who died were younger and had worse cardiac compromise pre-NA.
• NA improved tissue perfusion, with tachycardia (31%) and transient hypertension (2.7%) as main adverse effects.

Conclusions:

• Noradrenaline (NA) demonstrates effectiveness in supporting neonates with cardiovascular compromise.
• Further prospective research is recommended to evaluate NA as a first- or second-line inotropic agent.
• Standardized protocols for NA use in neonates may improve outcomes.